FBRX (Forte Biosciences) Future 3-5Y EPS without NRI Growth Rate : 40.54 (As of May. 08, 2025)

View and export this data going back to 2020. Start your Free Trial

What is Forte Biosciences Future 3-5Y EPS without NRI Growth Rate?

Future 3-5Y EPS without NRI Growth Rate is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Forte Biosciences's Future 3-5Y EPS without NRI Growth Rate is 40.54.

Competitive Comparison of Forte Biosciences's Future 3-5Y EPS without NRI Growth Rate

For the Biotechnology subindustry, Forte Biosciences's Future 3-5Y EPS without NRI Growth Rate, along with its competitors' market caps and Future 3-5Y EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Forte Biosciences's Future 3-5Y EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Forte Biosciences's Future 3-5Y EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Forte Biosciences's Future 3-5Y EPS without NRI Growth Rate falls into.

Save Embed

;

Save Embed

;

Forte Biosciences (NAS:FBRX) Future 3-5Y EPS without NRI Growth Rate Explanation

Future 3-5Y EPS without NRI Growth Rate s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Forte Biosciences Future 3-5Y EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Forte Biosciences's Future 3-5Y EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.

Forte Biosciences Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Forte Biosciences Inc (NAS:FBRX) » Definitions » Future 3-5Y EPS without NRI Growth Rate

Comparable Companies

Traded in Other Exchanges

37T:Germany

Address

3060 Pegasus Park Drive, Building 6, Dallas, TX, USA, 75247

Website

https://www.fortebiorx.com

Forte Biosciences Inc is a biopharmaceutical company that is advancing through preclinical trials its product candidate, FB-102, which is a proprietary therapeutic molecule with potentially broad autoimmune applications in such indications as graft-versus-host disease (GvHD), vitiligo, alopecia areata, and type 1 diabetes (T1D).

Executives

Antony A Riley	officer: Chief Financial Officer	C/O KRYSTAL BIOTECH, INC., 2100 WHARTON STREET, SUITE 701, PITTSBURGH PA 94538
Paul A. Wagner	director, officer: See Remarks	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
David W Gryska	director	749 N MARY AVE, SUNNYVALE CA 94085
Scott C. Brun	director	C/O CABALETTA BIO, INC., 2929 ARCH STREET, SUITE 600, PHILADELPHIA PA 19104
Hubert C Chen	officer: See remarks	C/O PFENEX INC., 10790 ROSELLE STREET, SAN DIEGO CA 92121
Stephen K Doberstein	director	129 ELSIE STREET, SAN FRANCISCO CA 94110
Barbara K Finck	director	C/O PROTINE DESIGN LAB, 3858 JACKSON ST, SAN FRANCISCO CA 94118
Thomas E Darcy	director	C/O SCIENCE APPLICATIONS INTL CORP, 10260 CAMPUS POINT DR., SAN DIEGO CA 92121
Donald Allen Williams	director	C/O PRYOR CASHMAN LLP, 7 TIMES SQUARE, NEW YORK NY 10036
Steven Kornfeld	director	C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Lawrence Eichenfield	director	C/O FORTE BIOSCIENCES, INC., 1124 W. CARSON ST., MRL BLDG 3-320, TORRANCE CA 90502
Patricia S Walker	director	5540 EKWILL ST STE D, SANTA BARBARA CA 93111
Steven Michael Oliveira	10 percent owner	18 FIELDSTONE COURT, NEW CITY NY 10956
Fairooz Kabbinavar	officer: SVP Clinical Development	C/O TOCAGEN INC., 4242 CAMPUS POINT COURT, STE. 500, SAN DIEGO CA 92121
Faheem Hasnain	director	14 CAMBRIDGE CENTER, CAMBRIDGE MA 02142